Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Specimen Handling 12Vincristine 8Magnetic Resonance Spectroscopy 7Leucovorin 5Doxorubicin 5Cyclophosphamide 5X-Rays 4Radiotherapy 4Etoposide 4Cytarabine 4Cisplatin 4pegaspargase 3Radiotherapy, Conformal 3Radiation 3Prednisone 3Pemetrexed 3Lenalidomide 3High-Energy Shock Waves 3Gemcitabine 3Dexamethasone 3Dactinomycin 3Carboplatin 3Biopsy 3pembrolizumab 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2dehydroftorafur 2daratumumab 2calaspargase pegol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × asparaginase erwinia chrysanthemi recombinant × 30 days × Clear all
NCT02981628 2026-06-05

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡